Sanofi Adr (SNY)

Oct 02, 2025

Leerink Partners Sticks to Its Buy Rating for Sanofi (SNYNF) - The Globe and Mail

Oct 02, 2025

Sep 29, 2025

BostInno🗳️ Vote in Inno Madness round two | 💻 UKG announces layoffs - The Business Journals

Sep 29, 2025

Sep 26, 2025

Sanofi Expands Insulin Savings Program To Cover All US Patients - Benzinga

Sep 26, 2025

Sep 17, 2025

Sanofi Reports Early Brivekimig Data, Signals Strong Efficacy And Good Tolerability - Sahm

Sep 17, 2025

Sep 16, 2025

AstraZeneca Puts Cambridge Expansion On Ice Adding Pressure On Starmer Ahead Of Trump Visit - Sahm

Sep 16, 2025

Sep 12, 2025

Sanofi: Informations relatives au nombre de droits de vote et d'actions - GlobeNewswire Inc.

Sep 12, 2025

Sep 10, 2025

Mandy Moore and Celebrity Mom Squad join Sanofi to help protect babies from RSV with BEYFORTUS® - Ariva

Sep 10, 2025

Sep 05, 2025

Leerink Partners Sticks to Their Buy Rating for Sanofi (SNY) - The Globe and Mail

Sep 05, 2025

Sep 04, 2025

What's Going On With Nektar Therapeutics Stock On Thursday? - Sahm

Sep 04, 2025

Sep 04, 2025

Why Is Sanofi Stock Falling Thursday? - Sahm

Sep 04, 2025

Sep 04, 2025

Sanofi Hit With Shock As Flagship Drug Successor Disappoints Investors - Sahm

Sep 04, 2025

Aug 26, 2025

New Report Highlights Community Health Workers' Impact, Calls for Sustained Local Investment, During National CHW Awareness Week - Ariva

Aug 26, 2025

Aug 21, 2025

European ADRs Under Pressure: Sector Divergence and Strategic Entry Points - AInvest

Aug 21, 2025

Aug 05, 2025

Dupixent Leads the Charge for Sanofi's Strong Portfolio in Immunology, Vaccines, and Rare Diseases - Morningstar

Aug 05, 2025

Aug 05, 2025

Janus Henderson Global Life Sciences Diversified ADR Managed Account Q2 2025 Commentary - Seeking Alpha

Aug 05, 2025

Jul 31, 2025

Sanofi ADR (SNY) Stock: A Year of Stock Market Ups and Downs - investchronicle.com

Jul 31, 2025

Jul 31, 2025

Sanofi ADR earnings beat by $0.63, revenue fell short of estimates - Investing.com Nigeria

Jul 31, 2025

Jul 27, 2025

INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of SanofiSNY - cnhinews.com

Jul 27, 2025

Jul 24, 2025

Sanofi: Reassessing Our Moat Rating for This Leader in Immunology, Vaccines, and Rare Diseases - Morningstar

Jul 24, 2025

Jul 22, 2025

BEYFORTUS® reduced hospital and doctor visits for RSV disease in babies by 87%, according to largest US real-world study - Ariva

Jul 22, 2025

Jul 21, 2025

AstraZeneca pledges $50 bln investment in US as pharma tariffs loom By Investing.com - Investing.com

Jul 21, 2025

Jul 14, 2025

INVESTOR ALERT: Pomerantz Law Firm Investigates Claims on Behalf of Investors of SanofiSNY - FinancialContent

Jul 14, 2025